Skip to content

Sublingual Misoprostol In Medical Treatment of First Trimester Missed Miscarriage

Sublingual Misoprostol 400 mcg and 800 mcg In Medical Treatment of First Trimester Missed Miscarriage: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05103098
Enrollment
200
Registered
2021-11-02
Start date
2021-11-01
Completion date
2023-03-31
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Miscarriage

Keywords

miscarriage, sublingual, misoprostol

Brief summary

The aim of this work is to compare the effectiveness of sublingual misoprostol 400 mcg versus 800 mcg for medical treatment of the first trimester missed miscarriage.

Detailed description

the study will be made on female patients with the first trimester missed abortion confirmed by ultrasound. Participants will be divided into 2 groups one group (A) will receive sublingual Misoprostol 400 mcg and the other group(B) will receive sublingual Misoprostol 800 mcg every 4 hours in both groups up to 3 doses the aim of the study is to compare the efficacy of sublingual Misoprostol in complete termination of the first trimester missed abortion and which route is the best will less side effects.

Interventions

DRUGmisoprostol 400 mcg

All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home. Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home. Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Sponsors

hany farouk
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

a double-blind randomized controlled trial

Intervention model description

a double-blind randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* All women above 18 years of age * Less than 12 weeks of gestation. * Pregnancy is confirmed by pregnancy test or ultrasound scan. * missed abortion * Normal general and gynecological examination.

Exclusion criteria

* Hemodynamically unstable. * Suspected sepsis with temperature 38 °C. * Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism, * respiratory illnesses, recent liver disease, or pruritus of pregnancy. * Presence of intrauterine contraceptive device (IUCD). * Suspect or proven ectopic pregnancy. * Failed medical or surgical evacuation before the presentation. * Known allergy to misoprostol.

Design outcomes

Primary

MeasureTime frameDescription
Completeness of abortion7 daysNumber of Participants with expulsion of Products of conception by visual inspection

Secondary

MeasureTime frameDescription
Successful medical abortion7 daysNumber of Participants with cervical os is closed with endometrial thickness of less than 15 mm
amount of calculated blood loss following treatment7 daysamount of calculated blood loss

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026